In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems are used in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. BRAF Tests are carried out to detect either the BRAF V600 mutant protein or mutations in the BRAF gene, using biopsied tissue, the outcome of which may guide therapies to treat melanoma cancer. GlobalData uses proprietary data and analytics to provide a comprehensive report on the braf tests devices market, including market shares of different players within Spain. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the braf tests market in Spain was F. Hoffmann-La Roche followed by bioMerieux, Qiagen, Amoy Diagnostics, Thermo Fisher Scientific, Abbott Laboratories and Biocartis Group.
BRAF Tests include BRAF Immunohistochemistry Tests, BRAF Nucleic Acid Amplification Tests (NAATs), BRAF Sanger Sequencing Tests, and BRAF Other Tests which includes In Situ Hybridisation (ISH) and Mass Array.
The value of the braf tests devices market within Spain was expected to be over $0.5m in 2023.
For the latest complete market share analysis of braf tests device market in Spain, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
